|
Nyxoah תציג בכנס השנתי ה-44 של J.P. Morgan Healthcare
מונט-סן-גיבר, בלגיה – 29 בדצמבר 2025, GLOBE NEWSWIRE –
Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH), חברת טכנולוגיות רפואיות המפתחת חלופות טיפול פורצות דרך לדום נשימה חסימתי בשינה (OSA) באמצעות נוירומודולציה, הודיעה היום כי צוות ההנהלה יציג בכנס השנתי ה-44 של J.P. Morgan Healthcare בסן פרנסיסקו ביום חמישי, 15 בינואר 2026. המצגת של החברה תחל בשעה 12:00 בצהריים לפי שעון פסיפיק PT .
Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference
Mont-Saint-Guibert, Belgium – December 29, 2025, GlobeNewswire:
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, Jan. 15, 2026. The Company's presentation will begin at 12:00 pm PT.
A live audio webcast of the presentation will be available online on the investor relations page of the Company’s website at investors.nyxoah.com.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Contact:
Nyxoah
John Landry, CFO
[email protected]
Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]
Attachment
*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire
לפרטים נוספים: נוי תקשורת 03-6026026 זהר 052-2641769
|
